Introduction
============

MicroRNAs (miRNAs or miRs) play important roles in development, cellular differentiation, proliferation, cell cycle control, and cell death ([@B1]). They are critical in development and progression of various kinds of diseases including cancer ([@B10]; [@B30]). Since it was found that the miRNA was involved in chronic lymphocytic leukemia, more and more miRNAs were identified to link with development and progression of cancers ([@B23]). It has been reported that miRNAs can regulate chemotherapeutic efficacy in multiple cancers ([@B21]; [@B22]). Hui-Ming Lin et al have discovered that miR-217 and miR-181b-5p significantly enhanced apoptosis in PC3 cells, indicating their therapeutic potential to improve taxane response in castration-resistant prostate cancer (CRPC) ([@B16]). Moreover, Bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs)-derived exosomes promote colon cancer stem cell-like traits via miR-142-3p, suggesting multiple ways of miRNAs in regulatiing cancer progression ([@B14]). As one of the original miRNAs discovered, the biological role of miR-3188 and its molecular mechanisms underlying cancer initiation and progression has been reported in nasopharyngeal carcinoma ([@B39]). Additionally, miR-3188 suppression could inhibit proliferation of breast cancer cells through regulating p27 expression. However, how it works in non-small cell lung cancer remains unclear.

Forkhead box protein O1 (FOXO1) is a protein encoded by the FOXO1 gene. FOXO1 shuttles between nucleus and cytoplasm back and forth. AKT phosphorylates FOXO1 and leads to FOXO1 translocate from nucleus to cytoplasm ([@B9]; [@B32]). Phosphorylated FOXO1 induces cell proliferation, inhibits cell apoptosis, and increases cell invasion and metastasis. Moreover, it also promotes angiogenesis and reduces cell apoptosis in chemotherapy and radiotherapy ([@B6]; [@B35]). AKT phosphorylation was induced by phospho-FOXO1 in NSCLC ([@B20]). However, the involvement of FOXO1 in inhibiting NSCLC cell proliferation is unrevealed.

PI3K/Akt/mTOR signaling pathway has been well characterized and recognized to play essential roles in lung cancer cell proliferation and survival. c-JUN was frequently overexpressed in NSCLC cells. miR-3188 was reported to suppress nasopharyngeal carcinoma cell growth through FOXO1-mediated mTOR-p-PI3K/AKT-c-JUN pathway. In this study, we investigated the interaction of miR-3188, mTOR, and FOXO1 in NSCLC cells. We hypothesized that miR-3188 also inhibit NSCLC cell proliferation via the same mTOR-p-PI3K/AKT-c-JUN signaling pathway. Indeed, we found miR-3188 expression was significantly higher in BEAS-2B cells than in NSCLC cells. miR-3188 mimics inhibited NSCLC cell growth both *in vitro* and *in vivo*. Overexpression of miR-3188 downregulated protein expression of mTOR and p-mTOR in NSCLC cells. And mTOR overexpression reverses inhibition of cell proliferation by miR-3188. More importantly, miR-3188 coordinates with FOXO1 through PI3K/AKT/c-JUN pathway. As such, miR-3188 may negatively modulate NSCLC cell growth by a FOXO1-modulating mTOR-p-PI3K/AKT-c-JUN signaling pathway. Our results suggested that miR3188 might be a potential therapeutic target for NSCLC treatment.

Materials and Methods {#s1}
=====================

Cell Culture and Synchronization
--------------------------------

Two NSCLC cell lines (A549 and H1299) and a human lung epithelial BEAS-2B cell line were obtained from Shanghai Cell Bank of the Chinese Academy of Sciences. NSCLC cell lines were cultured in RPMI-1640 (Invitrogen, Carlsbad, United States) supplemented with 10% fetal calf serum (FCS; Hyclone, Invitrogen, Carlsbad, United States). BEAS-2B was cultured in defined Keratinocyte serum free medium (KSFM, Invitrogen Carlsbad, United States) supplemented with epidermal growth factor (Invitrogen, Carlsbad, United States). The cells were maintained at 37°C with 10% CO~2~ in a humidified atmosphere.

In order to synchronize cells into G0 phase, NSCLC cells were starved with 0.1% FCS RPMI-1640 for 24--48 h. Cells were then further starved in serum free medium for another 48 h.

Cell Transfection
-----------------

FOXO1, c-JUN and mTOR siRNA or miR-3188 mimics and related inhibitor were obtained from RiboBio Inc. (Guangzhou, China). The sequences of primers used for miR-3188 mimics were: Sense 5′AGAGGCUUUGUGCGGAUACGGGG3′, Antisense 3′UCUCCGAAACACGCCUAUGCCCC5′. The sequences used for miR-3188 inhibitor was: 5′CCCCGUAUCCGCACAAAGCCUCU3′. mTOR and c-JUN plasmids were obtained from Biosense Technologies (Guangzhou, China). PI3K inhibitor Ly294002 was purchased from Sigma (St. Louis, United States). NSCLC cells were seeded onto a 6- or 96-well plate at 30--50% confluence before indicated transfection. Cells were transfected with plasmid, siRNA or miRNAs by using TurboFect siRNA Transfection Reagent (Fermentas, Vilnius, Lithuania) following the manufacturer's protocol. Cells were harvested 48--72 h later for further experiments.

Western Blotting
----------------

Cells were seeded into a 6-well plate and harvested when they reached 90--100% confluence. The detailed method was based on a previous publication ([@B36]). Antibodies included anti-FOXO1 (2880, 1:1000, CST), mTOR (04-385, 1:1000, millipore), p-mTOR (2971, 1:1000, CST), CCND1 (ab134175, 1:1000, Abcam), p21 (ab109199, 1:1000, Abcam), c-JUN (9165, 1:500, CST), AKT (9272, 1:1000, CST), pAKT (Ser473, 9271, 1:1000, CST), PI3K (4292, 1:1000, CST), p-PI3K (Tyr458, 4228, 1:1000, CST), p27 (2552, 1:1000, CST), and β-actin (ab8227, 1:1000, Abcam). The signal was visualized by using the Western Lightning^®^ ECL Pro Enhanced Chemiluminescence Substrate (PerkinElmer, United States) and exposed to X-ray film (Fujifilm, Japan).

Colony Formation Assay
----------------------

For colony formation assay, 100 cells/well NSCLC cells were cultured in 6-well culture plates. Cells were incubated at 37°C for 2 weeks. Colonies were stained with hematoxylin solution after 2 times washing with PBS. Cell clusters include more than 50 cells were identified as colonies. Colony counting was performed using a microscope (IX83; Olympus).

EdU Incorporation Assay
-----------------------

EdU incorporation assay was performed as previously described ([@B5]). Proliferating NSCLC cells were determined through the Cell-Light EdU Apollo 488 or 567 *in vitro* Imaging Kit (RiboBio, Guangzhou, China) based on the manufacturer's instruction. Briefly, NSCLC cells were incubated with 10 mM EdU for 2 h and then fixed with 4% paraformaldehyde. The fixed cells were permeabilized in 0.3% Triton X-100 for 5 min and stained with dyes accordingly. Cell nuclei were stained with DAPI (5 mg/ml) for 10 min. The number of EdU-positive cells was observed using a fluorescent Nikon microscope.

*In vivo* Tumorigenesis in Nude Mice
------------------------------------

Mice (BALB/C, nu/nu, 6--weeks-old, female) were subcutaneously injected with A549 and H1299 cells (5 × 10^6^/100 μl) transfected with miR-3188, FOXO1 or the control (*n* = 5 per group). All mice were housed in a pathogen-free conditions with controlled temperature (21 ± 2°C) and 12 h light-dark cycle. Food and water were available freely for mice. Three weeks later, the mice were sacrificed and tumor tissues collected for immnunohistochemical analysis.

Immunohistochemical Staining
----------------------------

Paraffin sections obtained from animal model were used for immunohistochemical staining for FOXO1, mTOR, Ki67, PCNA, or c-JUN expression. The results of immunohistochemical staining tissue sections were evaluated by two pathologists independently. The antibodies used were as follows: rabbit anti-FOXO1 (ab39670, 1:200, Abcam), anti-mTOR (04-385, 1:200, millipore), anti-PCNA (10205-2-AP, 1:50, PTG), anti-Ki67 (Ab16667, 1:50, Abcam), and anti-JUN (24909-1-AP, 1:200, PTG).

Statistical Analysis
--------------------

Statistical analysis was performed using SPSS 21.0 software. Data are presented as mean ± SD. Student's *t*-test was used to compare between two groups and one-way ANOVA (analysis of variance) analysis for multiple groups. All statistical tests were two-sided, and single, double and triple asterisks indicate statistical significance, ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, and ^∗∗∗^*P* \< 0.001.

Results
=======

miR-3188 Suppresses NSCLC Cell Growth
-------------------------------------

To investigate the involvement of miR-3188 in NSCLC development, we first detected its expression in human lung epithelial BEAS-2B cells and NSCLC A549 and H1299 cells. It was found that miR-3188 is overexpressed in NSCLC cells but its expression is low in BEAS-2B cells (Figure [1A](#F1){ref-type="fig"}). To further identify its biological function in NSCLC, miR-3188 mimics or inhibitors were, respectively introduced into A549 and H1299, or BEAS-2B cells. More than twofold increase in miR-3188 expression was observed in A549 and H1299 cells treated with miR-3188 mimics compared with the control group by qRT-PCR analysis (Student's *t*-test, with *P* \< 0.05 for both, Figure [1F](#F1){ref-type="fig"}). To examine the effect of miR-3188 expression on NSCLC cell growth *in vitro*, colony formation and Edu incorporation assay were performed. As expected, both A549 and H1299 cells transfected with miR-3188 mimics formed significantly less colonies (Figure [1B](#F1){ref-type="fig"}). Furthermore, the result of Edu incorporation assay shows that miR-3188 mimics efficiently decreased the number of cells in S phase, and this reduction was rescued by treating cells with miR-3188 inhibitor (Figure [1C](#F1){ref-type="fig"}). These results indicate that miR-3188 is capable of inhibiting cell proliferation and inducing G1/S transition in NSCLC cells.

![miR-3188 inhibits NSCLC cells proliferation through PI3K/AKT inactivation. **(A)** RT-PCR on miR-3188 expression in NSCLC cells and normal lung epithelial BEAS-2B cells. Mean ± SD, ^∗∗^*P* \< 0.01. **(B)** Colony formation, and **(C)** EdU incorporation assays on NSCLC cells performed after transfection with control (ctrl.), miR-3188 mimics, or inhibitor as indicated. Scale bar: 15 μm. **(D)** Tumorigenesis of NSCLC cells before and after transfection with miR-3188 mimics; *n* = 5/group. **(E)** Representative Ki67 and PCNA immunohistochemical staining of A549 and H1299 primary cancer tissues. Scale bar: 20 μm. **(F)** RT-PCR on relative mRNA expression of miR-3188. Student's *t*-test, mean ± SD, ^∗^*P* \< 0.05. **(G,H)** Western blotting on expression of PI3K, AKT, p-PI3K, p-AKT, c-JUN, CCND1, p27 and p21 following transfection of miR-3188 inhibitor or mimics in A549, H1299, and BEAS-2B cells. β-actin was used as a loading control.](fphar-09-01362-g001){#F1}

Next, an *in vivo* tumor formation experiment was performed through subcutaneous injection of A549-miR-3188 and H1299-miR-3188 or control cells into nude mice. Three weeks later, it was found that tumor size of the mice injected with A549-miR-3188 and H1299-miR-3188 cells was smaller than that of control cells (Figure [1D](#F1){ref-type="fig"}). Moreover, Ki67 and proliferating cell nuclear antigen (PCNA) expression were also lower in tumor tissues compared to that of control group (Figure [1E](#F1){ref-type="fig"}). These results suggest that miR-3188 inhibit tumorigenesis both *in vitro* and *in vivo*.

To investigate the mechanisms on how miR-3188 inhibits NSCLC cell proliferation, we performed Western blotting analysis on several biomarkers that regulate cell proliferation. It was found that miR-3188 overexpression reduced c-JUN and CCND1 expression, but increased expression of p27 and p21. miR-3188 inhibitors reverse the expression of these proteins (Figure [1G](#F1){ref-type="fig"}). Furthermore, p-PI3K and p-AKT expression reduced in miR-3188-overexpressing NSCLC cells (Figure [1H](#F1){ref-type="fig"}). These results indicate that phosphoinositide-3-kinase (PI3K)/AKT inactivation and c-JUN downregulation might be the mechanisms by which miR-3188 suppresses cell growth.

miR-3188 Targets mTOR
---------------------

It has been reported that mTOR is a direct target of miR-3188 ([@B39]). We found that overexpression of miR-3188 downregulated protein expression of mTOR and p-mTOR in NSCLC cells. In contrast, miR-3188 downregulation decreased mTOR and p-mTOR levels in BEAS-2B cells (Figure [2A](#F2){ref-type="fig"}). In mouse xenografts, immunohistochemistry in tumors from A549- and H1299-miR-3188 cells showed that mTOR expression was significantly downregulated (Figure [2B](#F2){ref-type="fig"}). Collectively, these data suggest that miR-3188 might directly target mTOR and reduce its expression, leading to inhibition of proliferation and tumorigenesis of NSCLC cells.

![miR-3188 regulates mTOR expression. **(A)** Western blotting on expression of mTOR and p-mTOR in miR-3188-overexpressing or miR-3188-inhibited A549, H1299 and BEAS-2B cells. β-actin was used as a loading control. **(B)** immunohistochemistry on mTOR expression in tumor tissue derived from A549 and H1299 cells. Scale bar: 20 μm.](fphar-09-01362-g002){#F2}

mTOR Overexpression Reverses Inhibition of Cell Proliferation by miR-3188
-------------------------------------------------------------------------

EdU incorporation assay indicated that mTOR overexpression in transfected miR-3188-overexpressing NSCLC cells resulted in increasing cell growth (Figure [3A](#F3){ref-type="fig"}). In mTOR overexpression groups, more cells in phase S were observed in both A549- and H1299-miR-3188 cells, suggesting that mTOR overexpression can restore NSCLC cell proliferation which was inhibited by miR-3188. Also, we observed that mTOR knockdown by siRNA remarkably reduced the expression of mTOR, p-mTOR, p-PI3K, p-AKT, CCND1 and c-JUN, and enhanced expression of p27 and p21 (Figure [3B](#F3){ref-type="fig"}). These results further confirmed that miR-3188 suppresses cell growth by directly targeting mTOR.

![mTOR expression restores miR-3188-mediated inhibition of cell proliferation. **(A)** EdU incorporation assay on cells transfected with control, ectopic mTOR or miR-3188 as indicated. Scale bar: 15 μm. **(B)** Western blotting on mTOR, p-mTOR, PI3K, P-PI3K, AKT, P-AKT, CCND1 and c-JUN expression in A549, H1299 and BEAS-2B cells. β-actin served as a loading control.](fphar-09-01362-g003){#F3}

FOXO1 Suppresses Cell Growth
----------------------------

It has been reported that FOXO1 induced PI3K/AKT signaling in gastric cancer. To evaluate the role of FOXO1 on NSCLC cell proliferation, we transfected a FOXO1 overexpressed lentiviral vector into NSCLC cells. FOXO1 markedly inhibited cell-cycle G1/S transition in NSCLC cells documented by EdU incorporation assay (Figure [4A](#F4){ref-type="fig"}). To further confirm that FOXO1 suppress NSCLC cell growth, *in vivo* tumorigenesis experiment was performed in nude mice. Successful overexpression of FOXO1 was confirmed by immunohistochemistry in A549 and H1299 tumors (Figure [4B](#F4){ref-type="fig"}). Tumor volumes were significantly smaller in tumors of FOXO1-overexpressing A549 and H1299 cells compared to control cells (Figure [4C](#F4){ref-type="fig"}). Ki67 expression in these tumors was also lower than that in controls (Figure [4D](#F4){ref-type="fig"}). These results indicate that FOXO1 negatively regulates tumor growth *in vivo*.

![FOXO1 inhibits NSCLC cells proliferation through PI3K/AKT pathway. **(A)** EdU incorporation assay on A549 and H1299 cells transfected with mock and/or FOXO1, siRNA as indicated. Scale bar: 15 μm. **(B)** Immunohistochemical staining of FOXO1 in xenograft tumors. Scale bar: 15 μm. **(C)** Reduced tumorigenicity in FOXO1 overexpressing A549 and H1299 cells; *n* = 5/group. **(D)** Immunohistochemistry of Ki67 in xenograft tumors. Scale bar: 20 μm. **(E)** Western blotting on PI3K, p-PI3K, AKT, p-AKT mTOR, p-mTOR, c-JUN, CCND1, p27 and p21 expression in NSCLC cells transfected with control and FOXO1, siFOXO1 or Ly294002 as indicated. β-actin served as a loading control. **(F)** Immunohistochemical staining of c-JUN in FOXO1 overexpressing xenograft tumors. Scale bar: 20 μm.](fphar-09-01362-g004){#F4}

FOXO1 overexpression reduced the expression of p-PI3K, p-AKT, mTOR and p-mTOR. Moreover, we observed that overexpression of FOXO1 also downregulated expression of c-JUN and CCND1 and upregulated expression of p21 and p27. Indeed, FOXO1 knockdown by siRNA exhibited the opposite results as shown in Figure [4E](#F4){ref-type="fig"}. Additionally, the effect of FOXO1 on the expression of p-PI3K, p-AKT, mTOR, p-mTOR, c-JUN, CCND1, p21 and p27 was significantly reduced in cells treated with Ly294002, the specific PI3K inhibitor (Figure [4E](#F4){ref-type="fig"}).

It has been reported that miR-3188 expression was downregulated by c-JUN, which is a downstream regulator of the PI3K/AKT pathway. Immunohistochemical staining result in FOXO1-overexpressing tumor tissues of mice showed decreased expression of c-JUN (Figure [4F](#F4){ref-type="fig"}). These results indicate that FOXO1 may mediate NSCLC cell growth and cell-cycle progression through the PI3K/AKT/c-JUN signaling pathway.

miR-3188 Coordinates With FOXO1 Through PI3K/AKT/c-JUN Pathway
--------------------------------------------------------------

A previous study showed that miR-3188 is a positive modulator of FOXO1 ([@B39]). miR-3188 inhibitor significantly rescue cell proliferation in Edu assay (Figure [4A](#F4){ref-type="fig"}). Expression of p-PI3K, p-AKT, c-JUN and CCND1 was enhanced, while expression of p27 and p21 were decreased in FOXO1-overexpressing NSCLC cells with miR-3188 inhibitor treatment, (Figure [5](#F5){ref-type="fig"}). These results indicate that miR-3188 coordinates with FOXO1 in suppressing NSCLC cell growth and support that the interaction of miR-3188 and FOXO1is through PI3K/AKT/c-JUN signaling pathway (Figure [6](#F6){ref-type="fig"}).

![FOXO1 and miR-3188 modulates expression of signaling molecules in A549 and H1299 cells. Western blotting on expression of p-PI3K, p-AKT, c-JUN, CCND1, p21 and p27 in FOXO1 overexpression and miR-3188 inhibition cells. β-actin served as a loading control.](fphar-09-01362-g005){#F5}

![A schematic diagram of FOXO1-mediated miR-3188-mTOR-p-PI3K/AKT-c-Jun signaling feedback loop in NSCLC.](fphar-09-01362-g006){#F6}

Discussion
==========

miRNAs have been reported to be associated with various types of cancers ([@B17]; [@B40]). However, the role of miR-3188 in NSCLC development has not been reported. In this study, we demonstrated that miR-3188 significantly suppressed proliferation and G1/S cell-cycle transition in NSCLC cells as well as growth of tumor xenografts, indicating that miR-3188 might be a tumor suppressor in NSCLC.

It is well known that tumor cell proliferation is associated with cell-cycle progression ([@B4]). We found that miR-3188 regulate NSCLC tumorigenesis by affecting cell cycle. We also identified that the role of miR-3188 is associated with other key signaling molecules including mTOR, PI3K/AKT and c-JUN, that suppress cell cycle transition, thus inhibiting cell growth.

mTOR is an oncogene and constitutively activated PI3K/Akt signaling pathway was observed in almost every types of tumors ([@B27]; [@B34]; [@B33]) including NSCLC ([@B8]). It is well known that PI3K/Akt is involved in cell survival, growth, proliferation, repair, migration and angiogenesis ([@B19]; [@B18]; [@B11]). In cancer cells, activation of signaling pathway could be realized by gene mutation or upstream signaling molecules ([@B28]; [@B15]). It has been well documented that mTOR could form a negative feedback loop with PI3K/AKT ([@B7]; [@B29]; [@B3]). In this study, we found that mTOR is one of the direct targets of miR-3188 and PI3K/AKT signaling was inhibited by miR-3188 overexpression. However, PI3K/AKT signaling activation was inhibited by mTOR in breast cancer ([@B13]; [@B24]), indicating differential effect of mTOR in different type of cancers. As such, c-JUN and p-mTOR that are PI3K/AKT downstream molecules increased in mTOR knockdown NSCLC cells, that was consistent with in miR-3188 overexpression cells. Furthermore, mTOR overexpression enhanced NSCLC cell proliferation suppressed by miR-3188. These results confirm that miR-3188 inhibits PI3K/AKT pathway by suppressing mTOR, leading to downregulation of c-JUN and p-mTOR.

c-JUN has been well known as a key player of cell proliferation ([@B31]), invasiveness and metastasis ([@B26]), and is one of the PI3K/AKT pathway downstream components ([@B2]; [@B37]). Subsequent experiments confirmed that c-JUN negatively mediates miR-3188 expression indicating the formation of a complex miR-3188-mTOR--pPI3K/AKT-c-JUN loop in NSCLC.

It was reported that FOXO1 is a negative regulator in various types of cancers ([@B38]; [@B12]). Consistent with previous reports, NSCLC cells in G1/S cell cycle transition and cell growth was significantly suppressed by FOXO1. In this study, FOXO1 overexpression inhibited PI3K/AKT signaling pathway mediated cell-cycle process in NSCLC cells. However, this finding is not consistent with that in gastric cancer ([@B25]). In NSCLC cells, c-JUN, p-mTOR and total mTOR expression were downregulated. Similar to miR-3188, FOXO1 also inhibits NSCLC cell proliferation through suppressing PI3K/AKT mediated cell-cycle process.

We also found that miR-3188 failed to promote the expression of FOXO1, indicating that miR-3188 might be a downstream molecule of FOXO1. Through blocking mTOR-mediated p-PI3K/AKT/p-mTOR signaling activation, effect of miR-3188 was suppressed. In this case, FOXO1 lost its inhibitory effects on c-JUN and cell cycle and subsequently induced cell growth in NSCLC cells. Taken together, miR-3188 could be a downstream component of FOXO1 signaling.

In summary, our study supports that miR-3188 could form a negative feedback loop through mTOR/PI3K/AKT/c-JUN pathway. This pathway was regulated by FOXO1 which results in suppression of cell proliferation in NSCLC cells.
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